Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naproxen sodium + diphenhydramine
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Naproxen sodium + diphenhydramine** is an oral fixed-dose over-the-counter analgesic and nighttime sleep-aid combination marketed by Bayer as **Aleve PM**. Each film-coated caplet contains naproxen sodium 220 mg and diphenhydramine hydrochloride 25 mg. Naproxen is a nonselective cyclooxygenase inhibitor that reduces prostaglandin-mediated pain and inflammation, while diphenhydramine is a sedating histamine H1 receptor inverse agonist used to help patients fall asleep and stay asleep. The product is indicated for temporary relief of occasional sleeplessness associated with minor aches and pains in adults and children aged 12 years and older. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82891458-ab0d-459a-8602-dcebd22c3010))
- Brand names
- Aleve PM
- Other names
- diphenhydramine + naproxen sodiumnaproxen sodium + diphenhydramine hydrochloridenaproxen sodium/diphenhydramine
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on naproxen sodium + diphenhydramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naproxen sodium + diphenhydramine.